Project Search

sector_ico_Health_trans Human Health

The Frontier Trial – Field Randomization of NA-1 Treatment In Early Responders

  • Project Leaders: Jim Christenson, Laurie Morrison
  • Institutions: University of British Columbia (UBC)
  • Budget: $4212084
  • Program/Competition: Partner Programs
  • Genome Centre(s): Genome British Columbia
  • Fiscal Year: 2016
  • Status: Closed

Stroke is a life threatening emergency caused by blocked arteries that affects 45,000 Canadians a year. Each hour a stroke is left untreated means brain cells are dying. The only emergency treatment we have is a clot busting agent that can re-open blocked arteries if given within 3-4.5 hours of the onset of stroke symptoms. Unfortunately only 5-11% of all Canadian stroke victims receive this treatment. If we could administer a treatment that could slow down or halt the damaging effects of stroke early after calling 911 it may improve outcomes. NA-1 is a drug developed by Canadian scientists which can be given to most stroke victims. This drug has been shown in animal models and patients, the ability to reduce damage of a stroke and improve brain function. The FRONTIER trial is designed to identify stroke patients early after calling 911 and compare outcomes when paramedics randomly give either NA-1 or a salt solution called a placebo and transport the patient to the closest stroke center. The team will follow the patients for up to 90 days after receiving the study drug to evaluate their brain function.